|Articles|February 1, 2022

VUS, CHEK2-related management in prostate cancer to be discussed in virtual genetics board

“We’re going to review CHEK2-related management guidelines, hereditary cancer implications for males and their families…and the importance of cascade testing,” says Veda N. Giri, MD.

In this video, Veda N. Giri, MD, previews the upcoming ENGAGEMENT study virtual genetics board’s February case discussion (https://www.prostategenetics.com/engagement). Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more